Apr 03, 2019 - WPX Energy's (WPX) subsidiary and joint venture partner in the Oryx II pipeline sign agreements to monetize its 25% interest in the Oryx II pipeline for $350 million.
Apr 08, 2019 - Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
Apr 12, 2019 - Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.
May 27, 2019 - Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Jun 10, 2019 - Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.
Jun 10, 2019 - American Airlines (AAL) extends 737 MAX cancellation period through Sep 3. Approximately, 115 flights are likely to be cancelled each day during the time frame.
Sep 06, 2019 - Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Sep 30, 2019 - Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
Dec 12, 2017 - Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.
Dec 20, 2017 - A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.